SCHEMBL20239262

SCHEMBL20239262

CNC(=O)NCCc1ccc(Oc2cc(CNc3ncc(Cl)cn3)cc(N)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.41
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
CYP3A4 P08684 1/20 0.38
OPRM1 P35372 5/20 0.38
OPRD1 P41143 5/20 0.38
VNN1 O95497 1/20 0.38
CNR1 P21554 1/20 0.37
FPR2 P25090 1/20 0.37
PLAAT3 P53816 1/20 0.37
PLAAT5 Q96KN8 1/20 0.37
PLAAT2 Q9NWW9 1/20 0.37
PLAAT4 Q9UL19 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239156 0.86 VNN1 (0.46) VNN1CNR1FPR2MEN1KMT2A
SCHEMBL28895887 0.83 VNN1 (0.41) ALDH1A1VNN1CNR1FPR2MEN1
SCHEMBL20239261 0.79 DGAT2 (0.51) DGAT2ALDH1A1RAB9ACYP3A4VNN1
SCHEMBL20239319 0.78 DGAT2 (0.60) DGAT2ALDH1A1RAB9ACYP3A4VNN1
SCHEMBL20239177 0.77 DGAT2 (0.49) DGAT2ALDH1A1RAB9ACYP3A4PLAAT3
SCHEMBL20239321 0.77 DGAT2 (0.46) DGAT2ALDH1A1RAB9AMEN1KMT2A
SCHEMBL20239223 0.77 VNN1 (0.47) CYP3A4VNN1CNR1FPR2MEN1
SCHEMBL20259236 0.77 LOXL2 (0.41) OPRM1OPRD1VNN1PLAAT3PLAAT5
SCHEMBL20239165 0.76 DGAT2 (0.47) DGAT2ALDH1A1RAB9ACYP3A4OPRM1
SCHEMBL18249766 0.75 PLAAT3 (0.44) OPRM1OPRD1VNN1PLAAT3PLAAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885ALDH1A1 1430/4885RAB9A 1170/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885ALDH1A1 1189/4885RAB9A 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.